GO:1901202 negative regulation of extracellular matrix assembly: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901202 (negative regulation of extracellular matrix assembly) describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of extracellular matrix (ECM) assembly.
• ECM assembly is a tightly controlled process; its negative regulation is essential for normal tissue architecture, and its dysregulation contributes to cancer, fibrosis, and developmental disorders.
• Key molecular players include lysyl oxidase (LOX), matrix metalloproteinases (MMPs), and semaphorins, which can inhibit ECM crosslinking or promote ECM degradation.
• The SWI/SNF chromatin-remodeling complex cooperates with transcription factors to regulate ECM-responsive gene expression, providing a nuclear mechanism for negative feedback on ECM assembly.
• Proteoglycans and glycosaminoglycans are critical ECM components whose synthesis and assembly are subject to negative regulation during odontogenesis and other developmental processes.
• Research methods to study GO:1901202 include CRISPR knockout/knock-in models, transcriptomics, proteomics, and imaging of ECM structure.
Description
The extracellular matrix (ECM) is a complex network of proteins and polysaccharides that provides structural support and biochemical signals to cells. Its assembly is a highly regulated process, and the Gene Ontology term GO:1901202, negative regulation of extracellular matrix assembly, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of ECM assembly. This regulation is critical for tissue homeostasis, and its disruption is associated with a wide range of pathologies, including cancer, fibrosis, and developmental abnormalities. Understanding the mechanisms that negatively regulate ECM assembly is therefore of broad biomedical importance. Recent studies have identified specific molecular players, such as lysyl oxidase (LOX) and semaphorins, that inhibit ECM crosslinking or modulate cell-matrix interactions. Additionally, the SWI/SNF chromatin-remodeling complex has been shown to cooperate with transcription factors to regulate ECM-responsive gene expression, providing a nuclear mechanism for negative feedback on ECM assembly. This article synthesizes current knowledge on GO:1901202, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and experimental approaches for investigation.
negative regulation of extracellular matrix assembly At A Glance
| GO ID | GO:1901202 |
|---|---|
| GO term | negative regulation of extracellular matrix assembly |
| Ontology | biological_process |
| Synonym | down regulation of extracellular matrix assembly, down-regulation of extracellular matrix assembly, downregulation of extracellular matrix assembly, inhibition of extracellular matrix assembly |
| Major function | Inhibits the assembly of the extracellular matrix, thereby modulating tissue structure and cell signaling. |
| Related processes | ECM organization, cell adhesion, tissue remodeling, development |
| Key regulators | Lysyl oxidase (LOX), matrix metalloproteinases (MMPs), semaphorins, SWI/SNF complex |
| Disease relevance | Cancer progression, fibrosis, developmental disorders, keratoconus |
What Is GO:1901202?
GO:1901202, negative regulation of extracellular matrix assembly, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of extracellular matrix assembly. In other words, it includes molecular events that inhibit the formation of the ECM, a structured network of proteins and polysaccharides that surrounds cells. This regulation can occur at multiple levels, from transcriptional control of ECM component genes to post-translational modification and degradation of ECM proteins.
Why Is negative regulation of extracellular matrix assembly Important in Cell Biology?
Negative regulation of ECM assembly is crucial for maintaining tissue architecture and preventing excessive matrix deposition. Dysregulation of this process can lead to pathological conditions such as cancer, where increased ECM assembly promotes tumor progression and chemotherapy resistance, or developmental disorders like keratoconus, where altered ECM assembly affects corneal structure. Understanding the molecular mechanisms that negatively regulate ECM assembly can provide insights into disease pathogenesis and identify potential therapeutic targets.
• Controls tissue homeostasis by preventing excessive ECM deposition.
• Influences cancer progression and metastasis by modulating the tumor microenvironment.
• Plays a role in developmental processes such as odontogenesis and bone mineralization.
• Dysregulation is linked to fibrotic diseases and connective tissue disorders.
• Provides targets for therapeutic intervention, e.g., LOX inhibitors in cancer.
• Involved in biofilm formation and microbial ECM regulation.
• Affects cell signaling and gene expression through ECM-cell interactions.
• Critical for understanding chemotherapy resistance in triple-negative breast cancer.
What Happens During negative regulation of extracellular matrix assembly?
Inhibition of ECM crosslinking enzymes
In simple terms: Enzymes that normally crosslink ECM proteins are blocked, making the matrix weaker.
Lysyl oxidase (LOX) is a copper-dependent enzyme that catalyzes crosslinking of collagen and elastin, thereby stabilizing the ECM. Negative regulation of ECM assembly can occur through inhibition of LOX activity or expression. For example, targeting LOX with specific inhibitors reduces ECM crosslinking and has been shown to overcome chemotherapy resistance in triple-negative breast cancer. This suggests that LOX-mediated crosslinking is a key step that can be negatively regulated to modulate ECM assembly.
Transcriptional repression of ECM genes
In simple terms: The cell reduces the production of ECM proteins by turning off their genes.
The SWI/SNF chromatin-remodeling complex cooperates with transcription factors to regulate ECM-responsive gene expression. This cooperation can lead to transcriptional repression of ECM component genes, thereby negatively regulating ECM assembly. For instance, specific transcription factors may recruit SWI/SNF to promoters of ECM genes, altering chromatin structure and reducing transcription. This nuclear mechanism provides a way for cells to respond to environmental cues by downregulating ECM production.
Proteolytic degradation of ECM components
In simple terms: Enzymes cut up ECM proteins, breaking down the matrix.
Matrix metalloproteinases (MMPs) are enzymes that degrade ECM components. While not explicitly cited in the provided references, the general principle is that increased MMP activity can reduce ECM assembly by cleaving matrix proteins. This is a common mechanism in tissue remodeling and cancer invasion. However, specific citations linking MMPs to GO:1901202 are not available in the provided list, so this mechanism is described generically.
Modulation by semaphorins
In simple terms: Guidance molecules called semaphorins can tell cells to produce less matrix.
Semaphorins are a family of proteins originally identified as axon guidance cues but now known to regulate vascular morphogenesis and ECM assembly. Semaphorin signaling can inhibit integrin-mediated adhesion and migration, indirectly affecting ECM assembly. For example, semaphorin 3A has been shown to inhibit angiogenesis and reduce ECM deposition in certain contexts. This highlights how semaphorins can negatively regulate ECM assembly.
Regulation by mineral components
In simple terms: Minerals in the matrix can influence how the matrix is built.
In bone and biofilm ECM, mineral components such as calcium phosphate and other minerals play a role in ECM assembly. Negative regulation of ECM assembly can involve preventing mineral deposition or altering the stenciling principle that guides mineralization. For instance, in biofilms, a novel mineral component of the ECM has been discovered, and its regulation affects biofilm structure. These examples illustrate that negative regulation can target mineralization processes.
Key Genes Involved in GO:1901202 negative regulation of extracellular matrix assembly
The following genes and proteins are key players in the negative regulation of extracellular matrix assembly, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LOX | Crosslinks collagen and elastin; inhibition reduces ECM assembly | Target in triple-negative breast cancer to overcome chemotherapy resistance |
| MMP1 | Degrades collagen; may negatively regulate ECM assembly | Potential target in cancer and fibrosis (generic role, no specific citation) |
| MMP2 | Degrades type IV collagen; involved in ECM remodeling | Studied in cancer invasion and angiogenesis (generic role) |
| MMP9 | Degrades ECM components; associated with inflammation | Marker in various cancers (generic role) |
| SEMA3A | Inhibits angiogenesis and ECM deposition | Studied in vascular morphogenesis |
| SWI/SNF complex | Chromatin remodeling; regulates ECM gene transcription | Cooperates with transcription factors to modulate ECM gene expression |
| TGFB1 | Induces ECM production; its inhibition reduces ECM assembly | Target in fibrosis (generic role) |
| CTGF | Promotes ECM synthesis; negative regulators may inhibit its activity | Studied in fibrosis (generic role) |
| SPARC | Modulates collagen assembly; can inhibit ECM assembly | Studied in cancer and development (generic role) |
| FMOD | Regulates collagen fibrillogenesis; may inhibit assembly | Studied in corneal development |
| KERA | Involved in corneal ECM assembly; mutations cause keratoconus | Genetic studies in keratoconus |
| LUM | Regulates collagen fibril assembly; can inhibit ECM assembly | Studied in corneal and skin disorders |
| DCN | Inhibits collagen fibrillogenesis; negative regulator of ECM assembly | Studied in fibrosis and cancer (generic role) |
| BGN | Modulates collagen assembly; may inhibit ECM assembly | Studied in bone and connective tissue (generic role) |
| ACAN | Major proteoglycan in cartilage; its degradation reduces ECM assembly | Studied in osteoarthritis (generic role) |
| HSPG2 | Perlecan; regulates ECM assembly and cell signaling | Studied in development and cancer (generic role) |
| COL1A1 | Major collagen; its downregulation reduces ECM assembly | Target in fibrosis (generic role) |
| COL1A2 | Collagen type I; negative regulation reduces ECM assembly | Studied in bone and skin (generic role) |
How Is negative regulation of extracellular matrix assembly Regulated?
The negative regulation of ECM assembly is controlled by various signaling pathways and transcription factors. The SWI/SNF chromatin-remodeling complex cooperates with transcription factors to regulate ECM-responsive gene expression, providing a nuclear mechanism for negative feedback. Additionally, lysyl oxidase (LOX) activity can be inhibited by specific inhibitors, leading to reduced ECM crosslinking. Semaphorins, such as SEMA3A, can inhibit integrin-mediated adhesion and migration, indirectly affecting ECM assembly. In bone, the stenciling principle for ECM mineralization involves regulatory factors that prevent excessive mineral deposition. These examples illustrate that negative regulation occurs at multiple levels, from transcription to post-translational modification.
negative regulation of extracellular matrix assembly and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LOX | Triple-negative breast cancer | Knockout or overexpression in cancer cell lines; xenograft models |
| KERA | Keratoconus | Knockout in corneal epithelial cells; patient-derived iPSCs |
| LUM | Keratoconus | Knockout in corneal fibroblasts; CRISPR knock-in of mutations |
| FMOD | Keratoconus | Knockout in corneal keratocytes; 3D corneal models |
| SEMA3A | Vascular morphogenesis | Knockout in endothelial cells; zebrafish models |
Cancer
In cancer, increased ECM assembly promotes tumor progression and chemotherapy resistance. Targeting lysyl oxidase (LOX) to inhibit ECM crosslinking has been shown to overcome chemotherapy resistance in triple-negative breast cancer. This suggests that negative regulation of ECM assembly can be therapeutically exploited. Additionally, ECM remodeling by MMPs and other enzymes contributes to invasion and metastasis, and their negative regulation may inhibit these processes.
Keratoconus
Keratoconus is a degenerative corneal disorder characterized by thinning and cone-shaped protrusion. Genetic studies have identified mutations in genes involved in ECM assembly, such as KERA, LUM, and FMOD, suggesting that defective negative regulation of ECM assembly contributes to disease pathogenesis. Understanding these mechanisms may lead to new treatments.
Fibrosis
Fibrotic diseases are characterized by excessive ECM deposition. Negative regulation of ECM assembly is impaired in fibrosis, leading to accumulation of collagen and other matrix proteins. Although specific citations are not provided, targeting pathways that negatively regulate ECM assembly, such as TGF-beta signaling, is a therapeutic strategy.
Biofilm-associated infections
In bacterial biofilms, the ECM is a key component of the biofilm matrix. A novel mineral component of the biofilm ECM has been discovered, and its regulation affects biofilm structure and antibiotic resistance. Negative regulation of ECM assembly in biofilms could be a target for anti-biofilm therapies.
From negative regulation of extracellular matrix assembly-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does LOX inhibition reduce ECM assembly and overcome chemotherapy resistance? | LOX knockout or overexpression in triple-negative breast cancer cell lines; xenograft mouse models |
| How do SWI/SNF complex mutations affect ECM gene transcription? | CRISPR knockout of SWI/SNF subunits in fibroblasts; RNA-seq and ChIP-seq |
| What is the role of KERA mutations in keratoconus? | Knock-in of patient mutations in corneal epithelial cells; 3D corneal organoids |
| How do semaphorins regulate ECM assembly in blood vessels? | SEMA3A knockout mice; endothelial cell culture |
| What is the function of mineral components in biofilm ECM? | Bacterial knockout of mineral-regulating genes; biofilm assays |
| How do proteoglycans regulate odontogenesis? | Knockout of proteoglycan genes in dental mesenchymal cells; tooth organ culture |
How to Study the negative regulation of extracellular matrix assembly Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression changes | Identify ECM genes downregulated by negative regulators |
| Proteomics | Protein abundance and modifications | Quantify ECM protein levels after LOX inhibition |
| Confocal microscopy | ECM structure and organization | Visualize collagen fibers in keratoconus models |
| Electron microscopy | Ultrastructure of ECM | Study mineral tessellation in bone |
| Collagen gel contraction assay | Cell-mediated ECM remodeling | Assess negative regulation of ECM assembly |
| LOX activity assay | Enzymatic crosslinking activity | Screen for LOX inhibitors |
| Biofilm assays | Biofilm ECM formation | Study mineral components in biofilm ECM |
| Odontogenesis organ culture | Tooth development and ECM assembly | Study proteoglycan function |
Transcriptomics and RNA-seq
RNA sequencing can measure changes in expression of ECM-related genes upon negative regulation. For example, knockout of SWI/SNF components alters ECM gene expression. This method provides a global view of transcriptional changes.
Proteomics and ECM composition analysis
Mass spectrometry-based proteomics can quantify ECM protein levels and modifications. This is useful to assess the impact of negative regulators on ECM assembly.
Imaging of ECM structure
Confocal microscopy and electron microscopy can visualize ECM architecture. For instance, mineral tessellation in bone can be imaged to study negative regulation of mineralization.
Functional assays for ECM assembly
In vitro assays such as collagen gel contraction, cell adhesion, and crosslinking assays can measure ECM assembly. LOX activity assays are used to assess crosslinking inhibition.
How CRISPR Can Be Used to Study GO:1901202 negative regulation of extracellular matrix assembly
Knockout
CRISPR knockout of genes that negatively regulate ECM assembly, such as LOX or SWI/SNF subunits, can reveal their causal role. For example, LOX knockout reduces ECM crosslinking and may sensitize cancer cells to chemotherapy. Knockout of KERA in corneal cells can model keratoconus.
Point Mutation
Introducing point mutations found in patients, such as those in KERA or LUM, can help understand how specific amino acid changes affect ECM assembly. This is particularly relevant for keratoconus, where missense mutations are common.
Knock-in
Knock-in of tagged versions of ECM proteins, such as fluorescently labeled collagen, allows real-time imaging of ECM assembly. This can be used to study the dynamics of negative regulation.
Overexpression
Overexpression of negative regulators, such as semaphorins or MMPs, can inhibit ECM assembly. For instance, overexpressing SEMA3A in endothelial cells reduces ECM deposition. This approach can validate the function of candidate negative regulators.
How EDITGENE Supports negative regulation of extracellular matrix assembly Research
Researchers studying negative regulation of extracellular matrix assembly-related genes often need to determine whether a candidate gene is causally involved in ECM regulation or merely correlated with it. EDITGENE provides a comprehensive suite of CRISPR services to enable precise genetic manipulation and functional validation.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of extracellular matrix assembly research.
Frequently Asked Questions About negative regulation of extracellular matrix assembly
What is GO:1901202?
GO:1901202 is the Gene Ontology term for negative regulation of extracellular matrix assembly, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of extracellular matrix assembly.
What genes are involved in negative regulation of extracellular matrix assembly?
Key genes include LOX, SEMA3A, KERA, LUM, FMOD, and components of the SWI/SNF complex.
How is negative regulation of ECM assembly studied?
Common methods include CRISPR knockout/knock-in, RNA-seq, proteomics, and imaging of ECM structure.
Why is negative regulation of ECM assembly important in cancer?
It can inhibit tumor progression and overcome chemotherapy resistance, as shown by targeting LOX in triple-negative breast cancer.
What diseases are associated with defective negative regulation of ECM assembly?
Diseases include cancer, keratoconus, fibrosis, and biofilm-associated infections.
What is the role of LOX in ECM assembly?
LOX crosslinks collagen and elastin; its inhibition negatively regulates ECM assembly and can sensitize tumors to chemotherapy.
How do semaphorins regulate ECM assembly?
Semaphorins such as SEMA3A inhibit angiogenesis and ECM deposition, acting as negative regulators.
What is the SWI/SNF complex's role in ECM gene expression?
SWI/SNF cooperates with transcription factors to regulate ECM-responsive gene expression, often repressing ECM genes.
Can CRISPR be used to study negative regulation of ECM assembly?
Yes, CRISPR knockout, knock-in, and overexpression models are powerful tools to dissect gene function in ECM regulation.
What are potential therapeutic targets for modulating ECM assembly?
LOX, MMPs, and semaphorins are promising targets for cancer and fibrosis therapies.
Conclusion
Negative regulation of extracellular matrix assembly (GO:1901202) is a critical biological process that maintains tissue homeostasis and prevents pathological ECM accumulation. Key regulators such as LOX, semaphorins, and the SWI/SNF complex have been identified, and their dysfunction is linked to cancer, keratoconus, and other diseases. Advances in CRISPR-based models and omics technologies are accelerating our understanding of this process, offering new avenues for therapeutic intervention. EDITGENE provides comprehensive services to support research in this field.
References
- 1. Saatci O et al.. 2020. Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer.. Nat Commun 11(1):2416 PMID: 32415208
- 2. McKee MD et al.. 2022. Mineral tessellation in bone and the stenciling principle for extracellular matrix mineralization.. J Struct Biol 214(1):107823 PMID: 34915130
- 4. Bussolino F et al.. 2006. Semaphoring vascular morphogenesis.. Endothelium 13(2):81-91 PMID: 16728327
- 5. Barcelo-Canton RH et al.. 2025. Genetics of Keratoconus: A Comprehensive Review.. Genes (Basel) 16(10) PMID: 41153364
- 6. Keren-Paz A et al.. 2020. A brick in the wall: Discovering a novel mineral component of the biofilm extracellular matrix.. N Biotechnol 56:9-15 PMID: 31706043
- 7. Chen J et al.. 2024. The Essential Role of Proteoglycans and Glycosaminoglycans in Odontogenesis.. J Dent Res 103(4):345-358 PMID: 38407002
- 8. Xu R et al.. 2007. Extracellular matrix-regulated gene expression requires cooperation of SWI/SNF and transcription factors.. J Biol Chem 282(20):14992-9 PMID: 17387179
